...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: What's going on with the Phase 2 ZEN-3694 mCRPC trial?

Interestingly enough on July 16 1 investor from the US paid $326,250 for shares and 1/2 warrants and 5 investors from Germany paid $2,153,250 for shares and 1/2 warrants.  Price $2.61 CDN per unit.  From Sedar

Share
New Message
Please login to post a reply